云南白药：百年老字号，持续变革稳增长

Investment Rating - The report gives an "Accumulate" rating for the company, marking its first coverage [10][15]. Core Insights - Yunnan Baiyao, a century-old Chinese brand, has shown consistent revenue and profit growth over the past three decades, with revenue increasing from 0.58 billion yuan in 1993 to 39.11 billion yuan in 2023, a growth of 673 times. The net profit rose from 0.13 billion yuan to 4.09 billion yuan in the same period, a growth of 314 times. The company has maintained a continuous dividend payout for over 30 years, with cumulative cash dividends reaching 26.62 billion yuan by September 30, 2024 [9][54][55]. - The company is undergoing organizational transformation to enhance its growth potential, including a mixed-ownership reform completed in 2019 and the implementation of a strategic plan for 2024-2028 [8][17]. Summary by Sections 1. Company Overview - Yunnan Baiyao was founded in 1902 and has evolved from a traditional Chinese medicine company to a leader in the health industry. The company has a strong brand reputation and a unique product formula classified as a national secret [9][36]. 2. Financial Performance - The company reported total revenue of 39.11 billion yuan in 2023, with a year-on-year growth rate of 7.2%. The net profit for the same year was 4.09 billion yuan, reflecting a significant increase of 36.4% compared to the previous year. For the first three quarters of 2024, revenue reached 29.92 billion yuan, a 0.76% increase year-on-year, while net profit was 4.33 billion yuan, up 4.93% [7][54]. 3. Business Segments - The company operates through four main business divisions: - Pharmaceutical Division: Core business with a revenue of 40.69 billion yuan in the first half of 2024, growing by 9.6% year-on-year [12]. - Health Products Division: Focused on oral care and personal health products, generating 31.44 billion yuan in revenue [12]. - Traditional Chinese Medicine Resources Division: Achieved 8.94 billion yuan in revenue, with a year-on-year growth of approximately 22% [12]. - Yunnan Provincial Pharmaceutical Company: Reported revenue of 121.9 billion yuan in the first half of 2024, with a net profit increase of 26% [12]. 4. Profit Forecast and Valuation - The forecasted net profits for 2024, 2025, and 2026 are 44.73 billion yuan, 48.92 billion yuan, and 53.55 billion yuan, respectively, with corresponding growth rates of 9.3%, 9.4%, and 9.5%. The estimated price-to-earnings ratios for these years are 23, 21, and 19 [10][15]. 5. Strategic Initiatives - The company is implementing a strategic plan focusing on integrating traditional Chinese medicine into modern life and enhancing its product offerings through innovation and technology [36][40]. 6. Dividend Policy - Yunnan Baiyao has a strong dividend policy, with a total cash dividend of 37.06 billion yuan proposed for 2023, representing 90.53% of the net profit for that year [55].